Testicular Microlithiasis: Clinical Manifestations and Management
Testicular microlithiasis is typically asymptomatic and requires no treatment or surveillance in men without additional risk factors for testicular cancer. 1
Clinical Manifestations
Testicular microlithiasis (TM) itself produces no symptoms. It is defined as the presence of >5 small echogenic non-shadowing foci on ultrasound, representing microscopic calcium deposits within seminiferous tubules 1. The condition is almost always discovered incidentally during scrotal ultrasound performed for other reasons.
Key point: TM is not a disease—it is an ultrasound finding that may or may not have clinical significance depending on the patient's risk profile.
Management Algorithm
Step 1: Assess for Risk Factors
The management of TM depends entirely on whether additional risk factors for germ cell tumors are present:
High-risk factors include:
- Cryptorchidism (undescended testis)
- Personal history of testicular cancer
- Family history of testicular cancer
- Infertility/subfertility
- Testicular atrophy (<12 ml volume)
- Germ Cell Neoplasia In Situ (GCNIS) 1, 2, 3
Step 2: Risk-Stratified Management
For Isolated TM WITHOUT Risk Factors:
No further evaluation is required. 1, 2
- Do NOT perform: testicular biopsy, follow-up ultrasound, tumor markers (AFP, hCG, LDH), or CT imaging 3
- Recommend: monthly testicular self-examination 3, 4
- Rationale: Prospective studies show no association between isolated TM and development of germ cell tumors 1. The cancer risk is equivalent to the general population 5
This represents a strong recommendation from both the 2019 AUA Guidelines and 2022 ACR Appropriateness Criteria, which explicitly state that isolated TM "does not confer an increased risk of malignant neoplasm" 1, 2.
For TM WITH Risk Factors:
Consider testicular biopsy in the following high-risk scenarios 3:
- Infertile men with TM
- Bilateral TM with atrophic testes
- History of cryptorchidism
- Personal history of testicular cancer
Surveillance approach includes:
- Monthly testicular self-examination (mandatory)
- Periodic scrotal ultrasound (timing individualized based on risk burden)
- Baseline tumor markers (AFP, hCG, LDH) if solid mass develops 1
Step 3: If Solid Mass Develops
Any solid testicular mass must be managed as malignant until proven otherwise 1:
- Obtain serum tumor markers (AFP, hCG, LDH) before any intervention
- Perform scrotal ultrasound with Doppler
- Counsel regarding fertility preservation (sperm banking)
- Proceed to radical inguinal orchiectomy or testis-sparing surgery for masses <2 cm in highly selected cases
Common Pitfalls to Avoid
Do not over-surveil isolated TM. The 2019 AUA Guidelines and 2022 ACR Guidelines both emphasize that routine imaging surveillance in men with isolated TM wastes resources and causes unnecessary anxiety without improving outcomes 1, 2.
Do not confuse TM with a testicular mass. TM appears as multiple tiny echogenic foci without posterior shadowing, while testicular tumors are hypoechoic masses with vascular flow on Doppler 1.
Do not order MRI for initial evaluation. MRI should not be used as the initial diagnostic modality for testicular lesions 1.
Evidence Quality
The recommendation against surveillance for isolated TM is based on Grade C evidence (Moderate Recommendation) from the 2019 AUA Guidelines 1, supported by prospective studies showing no increased cancer risk. The 2022 ACR Guidelines 2 and 2025 EAU Guidelines on male infertility 3 provide concordant recommendations, representing the most recent high-quality guideline consensus.
The key distinction is that TM only increases testicular cancer risk when it occurs in conjunction with established risk factors—it does not independently cause cancer 2, 5.